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Abstract
Background: There is a worldwide increase in the prevalence of obesity and disturbances in
glucose metabolism. The aim of this study was to assess the current prevalence of obesity, central
obesity and abnormal glucose tolerance in Finnish population, and to investigate the associations
between body mass index (BMI), waist circumference and abnormal glucose tolerance.
Methods: A cross-sectional population-based survey was conducted in Finland during October
2004 and January 2005. A total of 4500 randomly selected individuals aged 45–74 years were invited
to a health examination that included an oral glucose tolerance test. The participation rate was 62%
in men and 67% in women.
Results: The prevalence of obesity was 23.5% (95% Confidence Interval (CI) 21.1–25.9) in men,
and 28.0% (95% CI 25.5–30.5) in women. The overall prevalence of abnormal glucose tolerance
(including type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose) was 42.0% (95%
CI 39.2–44.8) in men and 33.4% (95% CI 30.9–36.0) in women. The prevalence of previously
unknown, screen-detected type 2 diabetes was 9.3% (95% CI 7.7–11.0) in men and 7.3% (95% CI
5.9–8.7) in women. Central obesity was associated with abnormal glucose tolerance within each of
the three BMI categories normal (< 25 kg/m2), overweight (25–29 kg/m2), and obese (≥ 30 kg/m2).
Conclusion: In a population-based random sample of Finnish population, prevalences of obesity,
central obesity and abnormal glucose tolerance were found to be high. A remarkably high number
of previously undetected cases of type 2 diabetes was detected. Waist circumference is a predictor
of abnormal glucose tolerance in all categories of obesity.
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Background
The increasing prevalence of obesity and sedentary life-
style are the major underlying causes for type 2 diabetes
(T2D) to become one of the fastest growing public health
problems worldwide, imposing a high financial burden
on health care costs [1,2]. The World Health Organization
(WHO) has estimated that the number of adults with dia-
betes will more than double from an estimated 143 mil-
lion in 1997 to 300 million by 2025 [3].
The prevalence of T2D in the 45–64 years-old population
in Finland has been found to be 10.2% in men and 7.4%
in women in 1992 [4]. The study conducted in Finland
observed that there was a large number of clinically undi-
agnosed T2D cases [4]. This finding together with the data
from the Diabetes Epidemiology – Collaborative analysis
Of Diagnostic Criteria in Europe (DECODE) study based
on earlier surveys [5] give reason to assume that the cor-
rect prevalence of diabetes in the population is markedly
higher than recognized.
Abnormal glucose tolerance such as impaired glucose tol-
erance (IGT) and impaired fasting glucose (IFG) are mod-
ifiable risk factors of T2D and cardiovascular diseases
[6,7]. Several studies have shown that the risk of develop-
ing abnormal glucose tolerance including T2D is closely
linked to the presence and duration of overweight and
obesity [8-10]. Indeed, 90% of individuals with T2D are
either overweight or obese [3]. Furthermore, there is suffi-
cient evidence from several studies to conclude that life-
style intervention in people with IGT can result in
sustained lifestyle changes and a reduction in diabetes
incidence [11-16].
Given the current knowledge that visceral fat is metaboli-
cally more dangerous than subcutaneous fat, it is surpris-
ing that there is only limited information available about
the association between the risk of abnormal glucose tol-
erance among overweight and obese people with increas-
ing waist circumference [17-19].
The aims of this study were to investigate the current prev-
alence of obesity, central obesity and abnormal glucose
tolerance as well as the associations between body mass
index (BMI), waist circumference and abnormal glucose
tolerance among 45–74 year-old Finnish men and
women, and to assess whether the prevalence of abnormal
glucose tolerance is associated with increased central
obesity among people who are normal weight, overweight
or obese.
Methods
The FIN-D2D survey was carried out in hospital districts
of Pirkanmaa, South Ostrobothnia and Central Finland
during October 2004 and January 2005. A random sam-
ple of 4500 subjects aged 45–74 years, stratified according
to sex, 10-year age groups (45–54, 55–64, and 65–74
years) and the three geographical areas, was selected from
the National Population Register in September 2004. The
study participants were invited to a clinical examination
by mail. Together with the invitation, they also received a
self-administered questionnaire on socioeconomic back-
ground, medical history, and health behavior. They were
asked to complete the questionnaire at home, and bring it
to the health examination.
Health examination was carried out according to the
WHO MONICA project protocol [20]. Height, weight and
waist circumference were measured by nurses specially
trained for the survey procedures. Height was measured to
the nearest 0.1 cm. Weight was measured in light clothing.
Waist circumference was measured to the nearest cm. The
examination also included an oral glucose tolerance test
(OGTT), which was carried out according to the WHO rec-
ommendations [21]. A 300 ml test solution contained 75
g anhydrous glucose and 1.6 g citric acid. The test started
after overnight fasting, and the 2-hour blood sample was
obtained 120 minutes after the ingestion of the solution.
Fasting and 2-hour samples for the plasma glucose deter-
mination were drawn into fluoridated tubes and centri-
fuged within 30 minutes. Plasma glucose was determined
with a hexokinase method (Thermo Fisher Scientific Oy,
Vantaa, Finland). All assays were performed at Laboratory
of Analytical Biochemistry in National Public Health
Institute, Helsinki.
Definitions
Glucose tolerance was classified according to the WHO
1999 criteria [21]. Individuals who reported that they
have diabetes were not included in the OGTT. Individuals
who reported that they had diabetes onset at the age of
younger than 35 years, and were treated with insulin from
the diagnosis of their disease were classified as having type
1 diabetes. They constituted approximately 5% of all indi-
viduals who reported having diabetes, and they were not
included in the type 2 diabetes prevalence calculations as
persons with disease.
Individuals who had not T2D, and had fasting plasma glu-
cose level ≥ 7.0 mmol/l or 2 h plasma glucose ≥ 11.1
mmol/l were classified as having screen-detected type 2
diabetes (ST2D). Those with 2 h plasma glucose ≥ 7.8 and
< 11.1 mmol/l, and fasting plasma glucose < 7.0 mmol/l
were classified as having IGT. IFG was defined as fasting
plasma glucose ≥ 6.1 but < 7.0 mmol/l, and 2 h plasma
glucose < 7.8 mmol/l. Subjects with T2D, ST2D, IGT or
IFG were classified as having abnormal glucose tolerance.
BMI was calculated as weight (kg) divided by height2
(m2). Central obesity was defined with the WHO criteriaBMC Public Health 2008, 8:423 http://www.biomedcentral.com/1471-2458/8/423
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[22]: waist circumference ≥ 102 cm and ≥ 88 cm in men
and women, respectively. In addition, central obesity in
the International Diabetes Federation (IDF) definition of
metabolic syndrome was also used: ≥ 94 cm in men and ≥
80 cm in women [23].
The overall participation rates are given in the table 1. In
addition to non-participants, individuals who were non-
fasting at the time of blood sample or had other problems
with OGTT were excluded from the analyses (Table 1).
Totally, 1364 men and 1461 women were included in the
analyses.
Ethical considerations
The study protocol was approved by the research ethics
committee of The Hospital District of Helsinki and Uusi-
maa. All the participants gave their written informed con-
sent prior participation to the study.
Statistical methods
Differences in glucose regulation by age groups, obesity
and central obesity were compared with logistic regression
models, using likelihood-ratio tests. Odds ratios for
abnormal glucose regulation were calculated using the
lowest obesity or central obesity category as the reference
group. Analyses were done separately in both sexes, and
adjusted for age and geographical area of living. The esti-
mates of total prevalences in the age group 45–74 years
were calculated taking into account the stratified sampling
design used in the study. In addition, people were catego-
rized jointly by BMI and waist circumference, and the pro-
portion of participants with abnormal glucose regulation
was assessed in each category, adjusting for age and sex.
Analyses were performed with the statistics package Stata
version 9.2 [24].
Results
Table 1 shows the baseline characteristics of the study par-
ticipants separately according to sex and 10-years age
groups (Table 1). The overall response rate was 62% in
men and 67% in women, respectively. The mean BMI was
27.6 in both men and women. The prevalence of obesity
was 23.5% (95% CI 21.1–25.9) in men, and 28.0% (95%
CI 25.5–30.5) in women. Central obesity increased with
age in both men and women.
The total prevalence of T2D increased from 8.6% in the
youngest age group to 24.9% in the oldest age group in
men, and from 4.8% to 20.4% in women (Table 2). ST2D
accounted for 57% in men and 65% in women of all prev-
alent cases of T2D. IGT and total abnormal glucose toler-
ance, including T2D, increased in both men and women
with increasing age. Overall, abnormal glucose tolerance
was observed in 42% of men and in 33% of women.
Of all individuals who were categorized as having ST2D,
55% were identified with elevated 2 h plasma glucose val-
ues only, 17% with elevated fasting glucose values only,
and 28% had both fasting and 2 h glucose values elevated.
The importance of the OGTT to identify diabetes
increased with increasing age; in the age group 45–54
years 42% of screen-detected diabetic cases were identi-
fied with the OGTT only, compared with 63% in the age
group 65–74 years.
Table 1: Characteristics of the study participants according to sex and age groups.
MEN WOMEN
45–54 55–64 65–74 Total 45–54 55–64 65–74 Total
Number of subjects, invited 750 750 750 2250 750 750 750 2250
Participated (%) 417 (55.6) 497 (66.3) 482 (64.3) 1396 (62.0) 493 (65.7) 525 (70.0) 482 (64.3) 1500 (66.7)
Excluded from analysis* 12 12 8 32 14 14 11 39
Age (years) 50.2 (2.8) 59.6 (2.8) 69.5 (2.9) 60.3 (8.3) 50.2 (2.9) 59.5 (2.8) 70.0 (2.8) 59.8 (8.5)
Weight (kg) 86.2 (14.8) 86.8 (14.9) 83.5 (13.6) 85.8 (14.5) 72.3 (13.8) 73.4 (13.8) 72.6 (13.8) 72.7 (13.8)
BMI (kg/m2) 27.3 (4.2) 27.9 (4.2) 27.7 (4.0) 27.6 (4.1) 27.0 (5.0) 27.8 (5.1) 28.4 (5.2) 27.6 (5.2)
BMI < 25 kg/m2, % 31.1 23.3 24.5 26.8 40.5 34.4 26.3 34.7
BMI 25–29 kg/m2, % 48.1 51.5 50.4 49.7 35.9 36.6 40.6 37.3
BMI ≥ 30 kg/m2, % 20.7 25.2 25.1 23.5 23.6 29.0 33.1 28.0
Waist (cm) 97.3 (11.9) 100.3 (12.0) 99.9 (11.4) 99.3 (11.8) 87.6 (12.9) 90.3 (13.3) 91.5 (13.7) 89.6 (13.4)
Central obesity, WHO#, % 30.6 38.6 39.9 37.4 43.4 52.6 59.0 50.9
Central obesity, IDF§, % 59.8 71.3 73.6 68.2 71.2 75.7 81.1 75.0
Data are presented as means (standard deviation) except where noted otherwise.
*Number of subjects excluded from the analyses due to following problems with OGTT: refused to participate in OGTT (n = 3); vomiting during 
OGTT (n = 3); fasting duration unknown or less than < 8 hours (n = 12); time for OGTT deviated by more than 15 minutes from the 2 hour limit 
(n = 15); other problems with the blood sample (n = 15).
#Central obesity, WHO: waist circumference ≥ 102 cm in men and ≥ 88 cm in women.
§Central obesity in the IDF definition of metabolic syndrome: waist circumference ≥ 94 cm in men and ≥ 80 cm in women.
Total is an estimate of the population prevalence in the age group 45–74 years, taking into account the stratified sampling used in the study.BMC Public Health 2008, 8:423 http://www.biomedcentral.com/1471-2458/8/423
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Men and women classified as obese (BMI = 30 kg/m2) had
a 5-fold increased risk for T2D compared with normal
weight people (Table 3). Odds ratios for T2D were 1.3 and
2.7 in overweight (BMI 25–29 kg/m2) men and women,
respectively, as compared to those with normal weight. In
addition, overweight and obese men and women had a
significantly higher prevalence of IGT and IFG compared
with normal weight people. Compared with normal
weight individuals, odds ratios for abnormal glucose tol-
erance were 1.8 and 2.3 for overweight men and women,
and 6.9 and 5.7 in obese men and women, respectively.
Table 2: Prevalence (95% confidence interval, CI) of type 2 diabetes (T2D), screen-detected type 2 diabetes (ST2D), total type 2 
diabetes (TT2D), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), abnormal glucose tolerance (AGT= TT2D, IGT, or 
IFG) in the study sample according to sex and age groups.
MEN WOMEN
45–54 55–64 65–74 Total p* 45–54 55–64 65–74 Total p*
n 405 485 474 1364 479 511 471 1461
T2D, % 2.7 8.2 12.2 7.1 < 0.001 2.3 3.5 8.3 3.9 < 0.001
(95% CI) (1.4–4.8) (6.0–11.1) (9.4–15.5) (5.7–8.5) (1.2–4.1) (2.1–5.5) (6.0–11.1) (2.9–4.9)
ST2D, % 5.9 8.7 12.7 9.3 0.002 2.5 8.0 12.1 7.3 < 0.001
(95% CI) (3.8–8.7) (6.3–11.5) (9.8–16.0) (7.7–11.0) (1.3–4.3) (5.8–10.7) (9.3–15.4) (5.9–8.7)
TT2D, % 8.6 16.9 24.9 16.4 < 0.001 4.8 11.5 20.4 11.2 < 0.001
(95% CI) (6.1–11.8) (13.7–20.5) (21.1–29.0) (14.3–18.5) (3.1–7.1) (8.9–14.6) (16.8–24.3) (9.6–12.8)
IGT, % 7.9 15.1 23.8 15.5 < 0.001 10.4 15.1 25.1 17.0 < 0.001
(95% CI) (5.5–11.0) (12.0–18.5) (20.1–27.9) (13.5–17.6) (7.8–13.5) (12.1–18.5) (21.2–29.2) (15.0–19.1)
IFG, % 9.9 12.4 5.9 10.0 0.002 5.2 5.1 4.2 5.2 0.746
(95% CI) (7.2–13.2) (9.6–15.6) (4.0–8.4) (8.2–11.8) (3.4–7.6) (3.4–7.4) (2.6–6.5) (3.9–6.5)
AGT, % 26.4 44.3 54.6 42.0 < 0.001 20.5 31.7 49.7 33.4 < 0.001
(95% CI) (22.2–31.0) (39.9–48.9) (50.0–59.2) (39.2–44.8) (16.9–24.4) (27.7–35.9) (45.1–54.3) (30.9–36.0)
*p-values are for test of equivalence (likelihood-ratio test) between the three age-groups
Total is an estimate of the population prevalence in the age group 45–74 years, taking into account the stratified sampling used in the study.
Table 3: Prevalence and odds-ratios (OR) with 95% confidence intervals of previously known type 2 diabetes (T2D), screen-detected 
type 2 diabetes (ST2D), total type 2 diabetes (TT2D), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), abnormal 
glucose tolerance (AGT = TT2D, IGT or IFG) of the study sample according to BMI category and gender.
MEN WOMEN
BMI BMI
< 25 25–29 ≥ 30 p* < 25 25–29 ≥ 30 p*
n 355 684 325 494 550 417
T2D, % 2.8 5.8 18.2 < 0.001 1.8 4.0 8.9 < 0.001
OR† 1.0 (ref) 2.05
(1.01–4.17)
7.59
(3.79–15.20)
1.0 (ref) 2.04
(0.92–4.49)
4.63
(2.20–9.77)
ST2D, % 7.0 6.4 17.5 < 0.001 2.6 8.2 12.5 < 0.001
OR 1.0 (ref) 0.90
(0.54–1.50)
2.81
(1.70–4.65)
1.0 (ref) 2.92
(1.55–5.51)
4.60
(2.45–8.62)
TT2D, % 9.9 12.3 35.7 < 0.001 4.5 12.2 21.3 < 0.001
OR 1.0 (ref) 1.25
(0.82–1.91)
5.27
(3.43–8.07)
1.0 (ref) 2.67
(1.61–4.41)
5.16
(3.15–8.45)
IGT, % 10.4 17.1 19.7 0.004 10.1 16.9 24.5 < 0.001
OR 1.0 (ref) 1.78
(1.19–2.65)
2.06
(1.32–3.22)
1.0 (ref) 1.63
(1.12–2.38)
2.58
(1.77–3.75)
IFG, % 5.9 9.2 13.5 0.002 2.0 4.5 8.6 < 0.001
OR 1.0 (ref) 1.65
(0.99–2.76)
2.63
(1.52–4.54)
1.0 (ref) 2.38
(1.13–5.02)
4.79
(2.33–9.83)
AGT, % 26.2 38.6 68.9 < 0.001 16.6 33.6 54.4 < 0.001
OR 1.0 (ref) 1.80
(1.34–2.42)
6.94
(4.88–9.85)
1.0 (ref) 2.34
(1.72–3.17)
5.69
(4.15–7.80)
*Likelihood-ratio test of equality, adjusted for age. †Age and geographical area adjusted odds ratios with 95% confidence intervals.BMC Public Health 2008, 8:423 http://www.biomedcentral.com/1471-2458/8/423
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Central obesity, measured by large waist circumference,
was associated with abnormal glucose tolerance within
each of the three BMI categories normal (< 25 kg/m2),
overweight, and obese (Table 4). The larger the waist cir-
cumference was, the higher the prevalence of any category
of abnormal glucose tolerance.
Table 5 shows the prevalence of ST2D, IGT, IFG and
abnormal glucose tolerance for different waist circumfer-
ence groups within the three BMI categories (Table 5).
Among overweight study participants, the prevalence of
abnormal glucose tolerance increased from 16% to 37%
among the three waist circumference categories (p <
0.001).
Discussion
In spite of raising concern about the global diabetes epi-
demic there are actually surprisingly few up to date reports
published in various countries on the size of the current
problem based on repeated cross-sectional population-
based surveys. Such surveys are the only way to assess the
situation at the population level and to monitor possible
changes in prevalence of T2D and other abnormalities in
glucose regulation.
This study assessed the prevalence of different categories
of abnormal glucose tolerance at baseline of the imple-
mentation of the Finnish T2D prevention programme in
three geographical areas in 2004 and 2005. In the survey,
a large number of previously undetected diabetes cases
were identified. As expected, both obesity and central
obesity were related to abnormal glucose tolerance.
Importantly, the risk of abnormal glucose tolerance
increased with increasing central obesity within each of
the obesity categories.
The overall prevalence of screen-detected diabetes of 9.3%
and abnormal glucose tolerance of 42.0% in men, and
7.3% and 33.4% in women, respectively, are all high. The
prevalence increased steadily with age, except that of IFG.
Our results are in line with the data from previous surveys
that many cases of diabetes remain undetected in the pop-
ulation since no systematic screening using an OGTT is
conducted [25-28]. Moreover, the proportion on previ-
ously undiagnosed cases of diabetes seems to be larger
than found in previous studies [29]. There seems to be suf-
ficient evidence from various countries in the world to
conclude that the undetected diabetes cases account for
30–60% of all diabetes cases. It is known that T2D often
starts slowly, virtually without typical symptoms of diabe-
tes. Thus, it is obvious that many cases of T2D remain
undiagnosed for years. Moreover, if only fasting glucose
measurements are used to screen for T2D, a significant
proportion of asymptomatic cases of diabetes remain
undetected, as also demonstrated by the DECODE study
[30].
Table 4: Prevalence and odds ratios (OR) with 95% confidence intervals of previously known type 2 diabetes (T2D), screen-detected 
type 2 diabetes (ST2D), total type 2 diabetes (TT2D), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), abnormal 
glucose tolerance (AGT = TT2D, IGT or IFG) of the study sample by waist circumference and gender
MEN WOMEN
WAIST CIRCUMFERENCE (cm) WAIST CIRCUMFERENCE (cm)
< 94 94–101 ≥ 102 p* < 80 80–87 ≥ 88 p*
n 427 437 500 351 355 755
T2D, % 2.1 5.5 15.2 < 0.001 2.0 2.5 6.9 < 0.001
OR† 1.0 (ref) 2.50
(1.14–5.47)
7.92
(3.89–16.11)
1.0 (ref) 1.20
(0.44–3.28)
3.12
(1.39–6.98)
ST2D, % 5.2 7.8 14.0 < 0.001 2.3 3.7 11.8 < 0.001
OR 1.0 (ref) 1.46
(0.83–2.55)
2.69
(1.63–4.46)
1.0 (ref) 1.56
(0.63–3.82)
5.00
(2.39–10.49)
TT2D, % 7.3 13.3 29.2 < 0.001 4.3 6.2 18.7 < 0.001
OR 1.0 (ref) 1.82
(1.14–2.89)
4.93
(3.24–7.51)
1.0 (ref) 1.40
(0.71–2.77)
4.48
(2.57–7.80)
IGT, % 9.6 18.1 19.6 < 0.001 8.8 15.2 21.2 < 0.001
OR 1.0 (ref) 1.92
(1.28–2.90)
2.01
(1.35–3.00)
1.0 (ref) 1.82
(1.13–2.93)
2.50
(1.65–3.79)
IFG, % 6.3 8.0 13.2 < 0.001 0.9 4.8 6.8 < 0.001
OR 1.0 (ref) 1.36
(0.80–2.29)
2.46
(1.53–3.96)
1.0 (ref) 5.97
(1.73–20.57)
8.71
(2.69–28.20)
AGT, % 23.2 39.4 62.0 < 0.001 14.0 26.2 46.6 < 0.001
OR 1.0 (ref) 2.05
(1.51–2.79)
5.23
(3.87–7.05)
1.0 (ref) 2.18
(1.47–3.23)
5.02
(3.56–7.08)
*Likelihood-ratio test of equality, adjusted for age. †Age and geographical area adjusted odds ratios including 95% confidence interval of odds ratios.BMC Public Health 2008, 8:423 http://www.biomedcentral.com/1471-2458/8/423
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Most previous studies have demonstrated an association
between development of glucose intolerance and
increased BMI [27,31-33] and waist circumference [25].
The Cooperative Health Research in the Region of Augs-
burg (KORA) survey conducted in 2000, showed that
both BMI and waist circumference were significantly
higher in men and women with abnormal glucose toler-
ance [25]. People with undetected diabetes had a higher
risk of being obese or having central obesity. The odds
ratios in men and women with undiagnosed diabetes
mellitus compared to non-diabetic subjects for obesity
were 1.9 and those for central obesity -1.9 in women and
2.6 in men. Zargar et al. reported a 2.3-fold increase in risk
of abnormal glucose tolerance in Asian Indian people
aged 40 years or over with BMI > 25 kg/m2 [28]. A waist-
to-hip ratio greater than 1 doubled the risk of abnormal
glucose tolerance.
Of all subjects who were categorized as ST2D, more than
half were identified with elevated 2 h plasma glucose val-
ues alone having normal fasting glucose values. Thus, the
findings of our study provide further scientific evidence
that the measurement of fasting glucose alone can not be
considered as the sole measurement in detecting abnor-
mal glucose regulation in non-diabetic subjects [5].
Surprisingly, there is only limited information available
about the prevalence of diabetes according to waist cir-
cumference within the BMI categories [18,19], [33,34].
Our results suggest that there seem to be difference in risk
of diabetes even within obese and overweight people
according to their waist circumference. Thus, reducing
central obesity while BMI remains stable may lower the
risk of diabetes.
T2D is characterized by a long preclinical phase including
early stages of glucose metabolism disorders such as IGT
and IFG [35]. Due to the long period without clinical
symptoms, up to 50% of the patients are not aware of
their disease [27,36,37] and macrovascular lesions are
observed in many diabetic patients already at the time of
diagnosis [26,38]. Several studies provided evidence that
lifestyle intervention in people with abnormal glucose tol-
erance can result in lifestyle changes which lead to a
reduction in diabetes incidence [11-15]. In the extended
follow-up of the Finnish Diabetes Prevention Study
(DPS), beneficial lifestyle changes and the corresponding
reduction in diabetes incidence were maintained for sev-
eral years after the individual lifestyle counseling was
stopped [16]. Therefore, screening for undetected cases of
T2D and implementing primary prevention measures
among high risk individuals (e.g. subjects with IGT or
IFG) might provide an optimal strategy to prevent many
late complications of diabetes on long-term. The results
from the Atherosclerosis Risk in Communities Study sug-
gested that screening strategies based on fasting plasma
glucose, complemented by clinical detection rules and/or
an OGTT, are effective and practical in the detection of
Table 5: Age- and sex-adjusted prevalence of screen-detected T2D, IGT, IFG and AGT by BMI and waist circumference categories.
MEN AND WOMEN BMI
Waist: < 25% (n) 25–29% (n) ≥ 30% (n)
ST2D < 94/< 80 3.7 (600) 3.0 (161) 0 (1)
94–101/80–87 5.6 (197) 5.1 (532) 5.6 (30)
≥ 102/≥ 88 8.1 (33) 9.2 (479) 15.9 (615)
p 0.065 0.010 0.097
IGT < 94/< 80 9.3 (600) 8.9 (161) 0 (1)
94–101/80–87 12.2 (197) 17.7 (532) 16.0 (30)
≥ 102/≥ 88 12.1 (33) 17.3 (479) 24.1 (615)
p 0.387 0.042 0.249
IFG < 94/< 80 3.2 (600) 3.6 (161) 0 (1)
94–101/80–87 5.1 (197) 6.4 (532) 2.6 (30)
≥ 102/≥ 88 0 (33) 8.1 (479) 12.9 (615)
p 0.569 0.032 0.099
AGT < 94/< 80 16.7 (600) 15.5 (161) 0 (1)
94–101/80–87 24.2 (197) 30.1 (532) 24.3 (30)
≥ 102/≥ 88 23.0 (33) 36.6 (479) 56.5 (615)
p 0.045 < 0.001 0.001
Excluding people with known diabetes from the calculations.
p: test of trend within the BMI category, adjusted for age and sex.BMC Public Health 2008, 8:423 http://www.biomedcentral.com/1471-2458/8/423
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hyperglycemic states meriting clinical intervention [39].
Moreover, the KORA survey calculated that the number
needed to screen (NNS) for undiagnosed diabetes was 6.5
for obese men and 9.7 for obese women, respectively 5.1
for men with central obesity (> 109 cm) and 8.5 for
women with central obesity (> 100 cm) [25]. On the other
hand, non-invasive and simple risk scores to detect undi-
agnosed diabetes or to predict the future probability of
T2D have been developed, one of them in Finland [40].
The Finnish Diabetes Risk Score is now used in Finland
nationwide as a part of the national prevention pro-
gramme for T2D [41].
The strengths of this study are that it is based on a large
representative sample of middle-aged men and women of
three hospital districts in Finland using oral glucose toler-
ance tests to detect glucose metabolism disorders. How-
ever, several limitations of this study need to be
considered. Despite efforts to increase the response rate,
only 56% of the men in the age-group 45 to 54 years
agreed to participate. The response rate was higher in
women and among older men. Non-participants might
have had already diabetes, and thus they have considered
unnecessary to take part in the survey. Therefore, the prev-
alence of known type 2 diabetes might have been under-
estimated. The reason for the low participation in younger
age groups may be due to the time constraint since the sur-
vey requires an attendance of at least two hours which
may be difficult to arrange for working people during the
day-time.
Conclusion
Testing for diabetes and impaired glucose regulation
using an OGTT in a population-based random sample
detected a remarkably high number of previously unde-
tected cases of type 2 diabetes in the Finnish population.
This study adds more evidence to justify opportunistic
diabetes screening in subjects with known cardiovascular
risk factors or history of cardiovascular disease as recently
emphasized. The main modifiable risk factors such as
obesity and central obesity were significantly related to a
higher prevalence of abnormal glucose tolerance in Fin-
land. Furthermore, the high prevalence of central obesity
and obesity among middle-aged Finnish people stresses
the importance and urgent implementation of strategies
for weight management in the general population in
order to decrease abnormal glucose tolerance, and in par-
ticular the onset of diabetes. Currently a national diabetes
prevention programme is ongoing in Finland, and its
effects will be evaluated by subsequent follow-up surveys
in the same target population of this study.
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